Trial reportPediatric nephrology (Berlin, Germany)2003
Cyclosporin A for the treatment of severe Henoch-Schönlein glomerulonephritis.
Trial report in Pediatric nephrology (Berlin, Germany), 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- National recommendations for the management of children and young people with IgA vasculitis: a best available evidence, group agreement-based approach.Archives of disease in childhood · 2024Guideline
- Cyclosporine A vs. methylprednisolone for Henoch-Schönlein nephritis: a randomized trial.Pediatric nephrology (Berlin, Germany) · 2011Trial
- IgA Vasculitis (Henoch-Schönlein Purpura): An Update on Treatment.Journal of clinical medicine · 2024Review
- Early clinical course of biopsy-proven IgA vasculitis nephritis.BMC pediatrics · 2022Article
- Individualized medication based on pharmacogenomics and treatment progress in children with IgAV nephritis.Frontiers in pharmacology · 2022Review
- Management of IgA Vasculitis with Nephritis.Paediatric drugs · 2021Review
- IgA vasculitis nephritis in children and adults: one or different entities?Pediatric nephrology (Berlin, Germany) · 2021Review
- Methylprednisolone or cyclosporine a in the treatment of Henoch-Schönlein nephritis: a nationwide study.Pediatric nephrology (Berlin, Germany) · 2019Article
- Successful Treatment of IgA Vasculitis Complicated with Bowel Perforation and Crescentic Glomerulonephritis by Combination Therapy of Glucocorticoid, Cyclosporine and Factor XIII Replacement.Internal medicine (Tokyo, Japan) · 2018Article
- Clinical outcomes in children with Henoch-Schönlein purpura nephritis without crescents.Pediatric nephrology (Berlin, Germany) · 2017Article
- Evaluation of Mycophenolate Mofetil and Low-Dose Steroid Combined Therapy in Moderately Severe Henoch-Schönlein Purpura Nephritis.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- The significance of tubulointerstitial lesions in childhood Henoch-Schönlein nephritis.Pediatric nephrology (Berlin, Germany) · 2016Article
- Methylprednisolone pulse therapy and intravenous cyclophosphamide therapy combined with cocktail therapy in severe pediatric Henoch-Schönlein purpura nephritis patient.CEN case reports · 2013Article
- Efficacy of triptolide for children with moderately severe Henoch-Schönlein purpura nephritis presenting with nephrotic range proteinuria: a prospective and controlled study in China.BioMed research international · 2013Article
- Chapter 11: Henoch-Schönlein purpura nephritis.Kidney international supplements · 2012Article
- Treatment of children with Henoch-Schönlein purpura nephritis with mycophenolate mofetil.Pediatric nephrology (Berlin, Germany) · 2012Article
- Improved outcome of Henoch-Schonlein purpura nephritis by early intensive treatment.Indian journal of pediatrics · 2012Article
- Clinical outcomes in children with Henoch-Schönlein purpura nephritis grade IIIa or IIIb.Pediatric nephrology (Berlin, Germany) · 2011Article
- Treatment strategies for Henoch-Schönlein purpura nephritis by histological and clinical severity.Pediatric nephrology (Berlin, Germany) · 2011Article
- Cyclosporin A therapy for Henoch-Schönlein nephritis with nephrotic-range proteinuria.Pediatric nephrology (Berlin, Germany) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated the efficacy of cyclosporin A (CyA) for treating pediatric patients with severe Henoch-Schönlein glomerulonephritis (HSP-GN) and nephrotic-range proteinuria. Seven pediatric HSP-GN patients (5 boys, 2 girls) were treated with CyA, with a mean age of 10.6 years at diagnosis (range 7.2-15.2 years) and mean follow-up times of 6.0 years (range 4.4-8.9 years) from diagnosis and 5.2 years (range 3.4-7.7 years) from the beginning of the CyA treatment. All had developed nephrotic-range proteinuria within 1-3 months of the HSP diagnosis. A renal biopsy was performed on all the patients, and two showed rapidly progressive glomerulonephritis. They all received additional angiotensin converting enzyme inhibitor medication and one to three types of immunosuppressive treatment had been tried in five of the seven patients before CyA was initiated at a mean interval of 0.7 years after diagnosis (range 0.1-2.0 years). All the patients responded to the CyA treatment within a mean of 1.4 months (range 1 week to 4 months). Four patients achieved a stable remission and had been without CyA treatment for a mean of 3.7 years (range 2.9-5.3 years) by the end of the follow-up. Three patients seemed to become CyA dependent, since they developed proteinuria when the treatment was stopped. CyA treatment had been started significantly earlier ( P=0.045) in the former group (mean 0.2 years, range 0.1-0.3 years) than in the latter (mean 1.5 years, range 1.2-2.0 years). Renal function was preserved in all patients, the glomerular filtration rate, plasma cystatin C, serum albumin, and serum creatinine being within normal limits at the end of the follow-up. We conclude that CyA treatment for severe treatment-resistant HSP-GN is promising, since four of the seven patients enjoy stable remission and all have retained their renal function after a mean follow-up of 6.0 years. However, some patients seem to develop CyA-dependent nephritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.